700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ ReadersThis Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Research Article Open Access
Objective: To explore therapeutic effects of thrombus aspiration catheter (TAC) combined with atorvastatin in reducing no-reflow in emergency percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI). Methods: A total of 126 AMI patients from January 2012 to June 2014 undergoing PCI but with slow flow or no-reflow were chosen as the study participants and divided into atorvastatin group and control group, each with 63 cases. The atorvastatin group received TAC treatment combined with atorvastatin while the control group received standard PCI treatment. Clinical records were then collected and analysed, including plasma high sensitive c-reactive protein (Hs-CRP) and soluble cell adhesion molecule-1 (sICAM-1) and serum pro B type natriuretic peptide (Pro-BNP). Thrombolysis in myocardial infarction (TIMI) grade 3 flow, heart function parameters and conditions of prognosis were also detected. Results: Preoperative and 24 h postoperative plasma Hs-CRP and sICAM-1 levels, and postoperative serum Pro-BNP level were lower in the atorvastatin group than those in the control group (all P<0.05). The percentages of infarct related artery (IRA) with TIMI grade 3 flow and postoperative ST segment resolution > 50% were higher, while creatine kinase-MB isoenzyme (CKMB) peak value, CKMB peak time, and occurrence rates of IRA no-reflow/slow flow and major adverse cardiovascular event (MACE) were lower in the atorvastatin group than those in the control group (all P<0.05). Conclusion: TAC combined with atorvastatin in the treatment of AMI patients after emergency PCI is safe, effective and worthy of clinical application.
AMI, TAC, Atorvastatin, PCI, Re-flow, Therapeutic effects, AMI, TAC, Atorvastatin, PCI, Re-flow, Therapeutic effects